The Role of Histone Deacetylase Inhibitors in Uveal Melanoma: Current Evidence

Uveal melanoma is the most common intraocular malignancy in adults, representing approximately 3% of all melanoma cases. Despite progress in chemotherapy, radiation and surgical treatment options, the prognosis and survival rates remain poor. Acetylation of histone proteins causes transcription of g...

Full description

Saved in:
Bibliographic Details
Published in:Anticancer research 2018-07, Vol.38 (7), p.3817-3824
Main Authors: Moschos, Marilita M, Dettoraki, Maria, Androudi, Sofia, Kalogeropoulos, Dimitrios, Lavaris, Anastasios, Garmpis, Nikolaos, Damaskos, Christos, Garmpi, Anna, Tsatsos, Michael
Format: Article
Language:English
Subjects:
Acetylation
Adults
Anticancer properties
Antitumor activity
Cell cycle
Cell growth
Cell proliferation
Chemotherapy
Deoxyribonucleic acid
DNA
DNA biosynthesis
Histone deacetylase
Inhibitors
Malignancy
Medical prognosis
Melanoma
Proteins
Radiation
Surgery
Transcription
Trichostatin A
Valproic acid
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Uveal melanoma is the most common intraocular malignancy in adults, representing approximately 3% of all melanoma cases. Despite progress in chemotherapy, radiation and surgical treatment options, the prognosis and survival rates remain poor. Acetylation of histone proteins causes transcription of genes involved in cell growth, DNA replication and progression of cell cycle. Overexpression of histone deacetylases occurs in a wide spectrum of malignancies. Histone deacetylase inhibitors block the action of histone deacetylases, leading to inhibition of tumor cell proliferation. This article reviewed the potential therapeutic effects of histone deacetylase inhibitors on uveal melanoma. MEDLINE database was used under the key words/phrases: histone deacetylase, inhibitors, uveal melanoma and targeted therapies for uveal melanoma. A total of 47, English articles, not only referring to uveal melanoma, published up to February 2018 were used. Valproic acid, trichostatin A, tenovin-6, depsipeptide, panobinostat (LBH-589), vorinostat (suberanilohydroxamic acid) entinostat (MS-275), quisinostat, NaB, JSL-1, MC1568 and MC1575 are histone deacetylase inhibitors that have demonstrated promising antitumor effects against uveal melanoma. Histone deacetylase inhibitors represent a promising therapeutic approach for the treatment of uveal melanoma.
ISSN:0250-7005
1791-7530
DOI:10.21873/anticanres.12665